Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Drake

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Experimental Biology and Medicine (Maywood, N.J.)|January 20, 2025
scRNA-seq reveals elevated interferon responses and TNF-α signaling via NFkB in monocytes in children with uncomplicated malariaCollins M Morang'a, Riley S Drake, Vincent N Miao, et al.
Journal of Medicinal Chemistry|September 3, 2004
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide coreTimothy J Ritchie, Edward K Dziadulewicz, Andrew J Culshaw, et al.
Cell Reports|February 12, 2025
Cellular rejuvenation protects neurons from inflammation-mediated cell deathSienna S Drake, Abdulshakour Mohammadnia, Aliyah Zaman, et al.
JCI Insight|March 22, 2021
Leukocyte dynamics after intracerebral hemorrhage in a living patient reveal rapid adaptations to tissue milieuBrittany A Goods, Michael H Askenase, Erica Markarian, et al.
Brain : a Journal of Neurology|August 15, 2019
MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitisBarbara Morquette, Camille A Juźwik, Sienna S Drake, et al.
British Journal of Pharmacology|February 29, 2000
Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesiaG M Burgess, M N Perkins, H P Rang, et al.
Medrxiv : the Preprint Server for Health Sciences|November 3, 2022
Severe COVID-19 is associated with fungal colonization of the nasopharynx and potent induction of IL-17 responses in the nasal epitheliumCarly G K Ziegler, Anna H Owings, Vincent N Miao, et al.
Journal of Medicinal Chemistry|May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonistsEdward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2021
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19Carly G K Ziegler, Vincent N Miao, Anna H Owings, et al.
Microbiology Spectrum|April 30, 2024
An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfectionCarly G K Ziegler, Anna H Owings, Michelle Galeas-Pena, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Experimental Biology and Medicine (Maywood, N.J.)|January 20, 2025
scRNA-seq reveals elevated interferon responses and TNF-α signaling via NFkB in monocytes in children with uncomplicated malariaCollins M Morang'a, Riley S Drake, Vincent N Miao, et al.
Journal of Medicinal Chemistry|September 3, 2004
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide coreTimothy J Ritchie, Edward K Dziadulewicz, Andrew J Culshaw, et al.
Cell Reports|February 12, 2025
Cellular rejuvenation protects neurons from inflammation-mediated cell deathSienna S Drake, Abdulshakour Mohammadnia, Aliyah Zaman, et al.
JCI Insight|March 22, 2021
Leukocyte dynamics after intracerebral hemorrhage in a living patient reveal rapid adaptations to tissue milieuBrittany A Goods, Michael H Askenase, Erica Markarian, et al.
Brain : a Journal of Neurology|August 15, 2019
MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitisBarbara Morquette, Camille A Juźwik, Sienna S Drake, et al.
British Journal of Pharmacology|February 29, 2000
Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesiaG M Burgess, M N Perkins, H P Rang, et al.
Medrxiv : the Preprint Server for Health Sciences|November 3, 2022
Severe COVID-19 is associated with fungal colonization of the nasopharynx and potent induction of IL-17 responses in the nasal epitheliumCarly G K Ziegler, Anna H Owings, Vincent N Miao, et al.
Journal of Medicinal Chemistry|May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonistsEdward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2021
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19Carly G K Ziegler, Vincent N Miao, Anna H Owings, et al.
Microbiology Spectrum|April 30, 2024
An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfectionCarly G K Ziegler, Anna H Owings, Michelle Galeas-Pena, et al.
Pageof 11